These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9949406)

  • 1. Bad blood and biologicals: the need for new radiopharmaceutical source materials.
    Perkins AC; Frier M
    Nucl Med Commun; 1999 Jan; 20(1):1-3. PubMed ID: 9949406
    [No Abstract]   [Full Text] [Related]  

  • 2. Biologicals: an attempt at classification and its implication for the viral safety of products.
    Horaud F
    Dev Biol Stand; 1993; 81():17-24. PubMed ID: 8174800
    [No Abstract]   [Full Text] [Related]  

  • 3. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Removal of TSE agents from blood products.
    Foster PR
    Vox Sang; 2004 Jul; 87 Suppl 2():7-10. PubMed ID: 15209867
    [No Abstract]   [Full Text] [Related]  

  • 5. Avoiding viral contamination in biotechnological and pharmaceutical processes.
    Henzler HJ; Kaiser K
    Nat Biotechnol; 1998 Nov; 16(11):1077-9. PubMed ID: 9831040
    [No Abstract]   [Full Text] [Related]  

  • 6. Creutzfeldt-Jakob verdict may prompt new claims.
    Carr K
    Nature; 1993 Nov; 366(6451):98. PubMed ID: 8232564
    [No Abstract]   [Full Text] [Related]  

  • 7. Public health. French Supreme Court ends tainted blood saga.
    Casassus B
    Science; 2003 Jun; 300(5628):2019. PubMed ID: 12829758
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationship between nature and source of risk and process validation.
    Berthold W; Werz W; Walter JK
    Dev Biol Stand; 1996; 88():59-71. PubMed ID: 9119164
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytokine contamination of biological products.
    Wadhwa M; Thorpe R
    Biologicals; 1997 Sep; 25(3):307-18. PubMed ID: 9324999
    [No Abstract]   [Full Text] [Related]  

  • 10. Membrane filtration for virus removal.
    Brandwein H; Aranha-Creado H
    Dev Biol (Basel); 2000; 102():157-63. PubMed ID: 10794103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies.
    Asher DM
    Dev Biol Stand; 1999; 99():41-4. PubMed ID: 10404874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future development of harmonized guidelines.
    Hayakawa T
    Dev Biol Stand; 1996; 88():331-2. PubMed ID: 9119158
    [No Abstract]   [Full Text] [Related]  

  • 13. Variant Creutzfeldt-Jakob disease and prions in the blood supply.
    Rohwer RG; Drohan W
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):84, 87, 131. PubMed ID: 16163166
    [No Abstract]   [Full Text] [Related]  

  • 14. Licensing of protein products from the milk of transgenic animals. Validation for pathogen removal--a strategy.
    Wright G; Colman A; Cottom D; Williams M
    Dev Biol Stand; 1996; 88():269-76. PubMed ID: 9119150
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost and public perception.
    Allain JP
    Dev Biol (Basel); 2000; 102():229-35. PubMed ID: 10794111
    [No Abstract]   [Full Text] [Related]  

  • 16. Worldwide perspective in transfusion safety: Europe.
    Reesink HW; Strengers PE
    Dev Biol (Basel); 2000; 102():205-10. PubMed ID: 10794107
    [No Abstract]   [Full Text] [Related]  

  • 17. Creutzfeld-Jacob disease and blood product recalls.
    Colvin R; Dubin C; Haas G
    Common Factor; 1994 Apr; (no 10):23. PubMed ID: 11362357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Viral safety: European and French directives].
    Rossi F; Legras JF
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S55-61. PubMed ID: 10896992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public health service recommendations for the use of vaccines manufactured with bovine-derived materials.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2000 Dec; 49(50):1137-8. PubMed ID: 11190118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Virus-free preparations of factor VIII].
    Graw J; Erfle V
    Dtsch Med Wochenschr; 1995 Feb; 120(7):221-4. PubMed ID: 7859646
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.